Citius Pharma closes $6M registered direct offering with warrants for up to $9.8M additional proceeds

Citius Pharmaceuticals, Inc.

Gross proceeds of $6M from sale of 4.92M shares/pre-funded warrants at $1.22 per share.
Short-term warrants to purchase up to 9.84M shares at $1.00; expire 24 months from issuance.
Net proceeds ~$5.455M after fees; used for LYMPHIR commercial launch and corporate purposes.
H.C. Wainwright placement agent; 7% cash fee plus placement agent warrants at $1.525 exercise.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.